[HTML][HTML] Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
New concepts and drugs have revolutionized medical treatment for cancers. These drugs,
which are very expensive and usually well tolerated, have dramatically improved cancer …
which are very expensive and usually well tolerated, have dramatically improved cancer …
Tyrosine kinase inhibitors in cancers: Treatment optimization–Part II
F Ferrer, P Tetu, L Dousset, C Lebbe, J Ciccolini… - Critical Reviews in …, 2024 - Elsevier
Real-life populations are more heterogeneous than those included in prospective clinical
studies. In cancer patients, comorbidities and co-medications favor the appearance of …
studies. In cancer patients, comorbidities and co-medications favor the appearance of …
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care
B Blanchet, A Xu-Vuilard, A Jouinot, F Puisset… - British Journal of …, 2024 - nature.com
Background Interindividual pharmacokinetic variability may influence the clinical benefit or
toxicity of cabozantinib in metastatic renal cell carcinoma (mRCC). We aimed to investigate …
toxicity of cabozantinib in metastatic renal cell carcinoma (mRCC). We aimed to investigate …
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer
K Takahashi, R Uozumi, T Mukohara… - The …, 2024 - academic.oup.com
Abstract Background Proton pump inhibitors (PPIs) reduce the bioavailability of several
anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 …
anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 …
[HTML][HTML] Combination use of first-line afatinib and proton-pump inhibitors reduces overall survival among patients with EGFFR mutant lung cancer
MC Ho, YS Chung, YC Lin, MS Hung… - OncoTargets and …, 2022 - ncbi.nlm.nih.gov
Purpose Previous retrospective studies reported that proton-pump inhibitors (PPIs) may
decrease the efficacy of first-generation epidermal growth factor receptor tyrosine kinase …
decrease the efficacy of first-generation epidermal growth factor receptor tyrosine kinase …
Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors …
K Uryu, Y Imamura, R Shimoyama, T Mase… - Cancer Chemotherapy …, 2024 - Springer
Purpose This study aimed to examine the prognostic impact of concomitant pH-regulating
drug use in patients with epidermal growth factor receptor (EGFR)-mutation-positive non …
drug use in patients with epidermal growth factor receptor (EGFR)-mutation-positive non …
[HTML][HTML] Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: A nationwide cohort …
C Bordet, M Zureik, Y Zelmat, M Lafaurie… - Cancer Treatment and …, 2024 - Elsevier
Introduction Previous studies have identified an interaction between protein kinase inhibitors
(PKIs) and proton pump inhibitors (PPIs) in patients with lung cancer. This type of interaction …
(PKIs) and proton pump inhibitors (PPIs) in patients with lung cancer. This type of interaction …
[HTML][HTML] Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer
S Di Cosimo, JM Pérez-García, M Bellet, F Dalenc… - The Breast, 2024 - Elsevier
Background The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility
at gastric pH> 4.5 and may have decreased activity when used with proton-pump inhibitors …
at gastric pH> 4.5 and may have decreased activity when used with proton-pump inhibitors …
[PDF][PDF] 医薬品と抗体薬物複合体(ADC) の相互作用に関する研究
清宮啓介， キヨミヤケイスケ - toyaku.repo.nii.ac.jp
複数の医薬品の併用において, 一方あるいは両方の医薬品の薬理効果が増強あるいは減弱する
ことがある. このような現象は, 薬物相互作用と呼ばれ, 治療の失敗や重篤な有害事象の発生の …
ことがある. このような現象は, 薬物相互作用と呼ばれ, 治療の失敗や重篤な有害事象の発生の …